All In Biotech

Free tool

FAERS Monitor: Vonjo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208712 or its brand name (Vonjo, Pacritinib Citrate). Reports on generic versions are filed under their own applications.

Reports

3,069

Serious

1,125

37% of reports

Hospitalization

571

Death reported

350

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea651
  • off label use623
  • fatigue388
  • product dose omission issue337
  • death314
  • nausea304
  • platelet count decreased297
  • haemoglobin decreased213
  • asthenia158
  • dizziness132
  • drug ineffective119
  • splenomegaly109
  • vomiting101
  • constipation94
  • dyspnoea89

Reports by year received

View as table
YearReports
20151
20173
20191
20201
20219
2022421
20231,102
2024750
2025493
2026288

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,090 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
splenomegalySignal10964.353.46,673
platelet count decreasedSignal29719.117.25,102
haemoglobin decreasedSignal21314.212.52,617
product dose omission issueSignal3377.97.12,038
diarrhoeaSignal6516.96.53,390
off label useSignal6234.94.51,999
fatigueSignal3883.43.1686
constipationSignal943.02.4121
astheniaSignal1582.92.5196
nauseaSignal3042.62.4318
deathSignal3142.52.2293
dizziness1321.81.549
vomiting1011.51.215
dyspnoea891.10.90
drug ineffective1190.60.529

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.